Liew L, Shome A, Wong W, Hong C, Hicks K, Jamieson S
Molecules. 2023; 28(11).
PMID: 37298933
PMC: 10254852.
DOI: 10.3390/molecules28114457.
Azad A, Kong A
Cancers (Basel). 2022; 14(19).
PMID: 36230623
PMC: 9563564.
DOI: 10.3390/cancers14194694.
Apilan A, Mothersill C
Int J Mol Sci. 2021; 22(16).
PMID: 34445354
PMC: 8395506.
DOI: 10.3390/ijms22168651.
Ni K, Lan G, Song Y, Hao Z, Lin W
Chem Sci. 2021; 11(29):7641-7653.
PMID: 34094142
PMC: 8159451.
DOI: 10.1039/d0sc01949f.
Luxford T, Pshenichnyuk S, Asfandiarov N, Perecko T, Falk M, Kocisek J
Int J Mol Sci. 2020; 21(21).
PMID: 33142925
PMC: 7662275.
DOI: 10.3390/ijms21218173.
Electron Ionization of Imidazole and Its Derivative 2-Nitroimidazole.
Meissner R, Feketeova L, Ribar A, Fink K, Limao-Vieira P, Denifl S
J Am Soc Mass Spectrom. 2019; 30(12):2678-2691.
PMID: 31667709
PMC: 6914720.
DOI: 10.1007/s13361-019-02337-w.
Low-energy electrons transform the nimorazole molecule into a radiosensitiser.
Meissner R, Kocisek J, Feketeova L, Fedor J, Farnik M, Limao-Vieira P
Nat Commun. 2019; 10(1):2388.
PMID: 31160602
PMC: 6546713.
DOI: 10.1038/s41467-019-10340-8.
Hypoxia-responsive lipid-poly-(hypoxic radiosensitized polyprodrug) nanoparticles for glioma chemo- and radiotherapy.
Hua L, Wang Z, Zhao L, Mao H, Wang G, Zhang K
Theranostics. 2018; 8(18):5088-5105.
PMID: 30429888
PMC: 6217062.
DOI: 10.7150/thno.26225.
Clinical trials targeting hypoxia.
Tharmalingham H, Hoskin P
Br J Radiol. 2018; 92(1093):20170966.
PMID: 29979089
PMC: 6435072.
DOI: 10.1259/bjr.20170966.
Nitroimidazoles as hypoxic cell radiosensitizers and hypoxia probes: misonidazole, myths and mistakes.
Wardman P
Br J Radiol. 2018; 92(1093):20170915.
PMID: 29303355
PMC: 6435051.
DOI: 10.1259/bjr.20170915.
Synthesis and Biological Evaluation of Iodoglucoazomycin (I-GAZ), an Azomycin-Glucose Adduct with Putative Applications in Diagnostic Imaging and Radiotherapy of Hypoxic Tumors.
Kumar P, Elsaidi H, Zorniak B, Laurens E, Yang J, Bacchu V
ChemMedChem. 2016; 11(15):1638-45.
PMID: 27377671
PMC: 5095876.
DOI: 10.1002/cmdc.201600213.
The impact of hypoxia and its modification of the outcome of radiotherapy.
Horsman M, Overgaard J
J Radiat Res. 2016; 57 Suppl 1:i90-i98.
PMID: 26983987
PMC: 4990104.
DOI: 10.1093/jrr/rrw007.
Modulation of the tumor vasculature and oxygenation to improve therapy.
Siemann D, Horsman M
Pharmacol Ther. 2015; 153:107-24.
PMID: 26073310
PMC: 4526350.
DOI: 10.1016/j.pharmthera.2015.06.006.
Texaphyrins and water-soluble zinc(II) ionophores: development, mechanism of anticancer activity, and synergistic effects.
Preihs C, Magda D, Sessler J
Bioinorg React Mech. 2014; 9(1-4):3-14.
PMID: 25295224
PMC: 4185204.
DOI: 10.1515/irm-2013-0001.
Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia.
Kizaka-Kondoh S, Konse-Nagasawa H
Cancer Sci. 2009; 100(8):1366-73.
PMID: 19459851
PMC: 11158459.
DOI: 10.1111/j.1349-7006.2009.01195.x.
Professor Tom Connors and the development of novel cancer therapies by the Phase I/II Clinical Trials Committee of Cancer Research UK.
Newell D, Searle K, Westwood N, Burtles S
Br J Cancer. 2003; 89(3):437-54.
PMID: 12888809
PMC: 2394365.
DOI: 10.1038/sj.bjc.6601106.
Detection of anaerobic odontogenic infections by fluorine-18 fluoromisonidazole.
Liu R, Chu L, Yen S, Chang C, Chou K, Wu L
Eur J Nucl Med. 1996; 23(10):1384-7.
PMID: 8781145
DOI: 10.1007/BF01367596.
Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation.
BREMNER J
Cancer Metastasis Rev. 1993; 12(2):177-93.
PMID: 8375020
DOI: 10.1007/BF00689809.
Pharmacokinetic and tumour-penetration properties of the hypoxic cell radiosensitizer desmethylmisonidazole (Ro 05-Ro-9963) in dogs.
White R, Workman P
Br J Cancer. 1980; 41(2):268-76.
PMID: 7370166
PMC: 2010189.
DOI: 10.1038/bjc.1980.39.
Is tumour radiosensitization by misonidazole a general phenomenon?.
Denekamp J, Hirst D, Stewart F, Terry N
Br J Cancer. 1980; 41(1):1-9.
PMID: 7362769
PMC: 2010178.
DOI: 10.1038/bjc.1980.1.
